English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, April 24, 2019
Eisai Selected as Competitive ICT Strategy Company for 2019
Monday, April 8, 2019
Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
エーザイ、新規線維芽細胞増殖因子(FGF)受容体選択的チロシンキナーゼ阻害剤「E7090」が厚生労働省の「先駆け審査指定制度」において対象品目に指定
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
エーザイ、「チョコラBB(R)スパークリング キウイ&レモン味」新発売
Friday, April 5, 2019
Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
エーザイ、シリーズ初の医薬部外品「トラベルミン(R)サポート」新発売
Friday, March 29, 2019
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
エーザイ、BACE阻害剤elenbecestatの早期アルツハイマー病を対象とした臨床第III相試験について安全性データモニタリング委員会が試験継続を推奨
Friday, March 22, 2019
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575